MATERNUS-Kliniken AG

MATERNUS-Kliniken AG

0.86
EUR
+0.01
(+0.58%)
0.11EPS
13.39P/E
29.78MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
5.42
5.82
5.88
5.92
6.06
5.93
5.93
5.45
5.31
5.09
4.88
5.44
5.63
5.92
Basic EPS, GAAP
-0.61
1.28
0.11
0.05
-0.07
-0.08
-0.49
-0.46
-0.12
-0.67
-0.68
-0.63
-0.66
0.11
Free Cash Flow per Basic Share
0.33
0.51
-0.25
0.34
0.41
0.25
0.72
0.55
0.73
0.11
-0.07
0.66
0.53
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.54
-0.28
-0.16
-0.11
-0.18
-0.26
-0.76
-1.09
-1.21
-1.87
-2.56
-3.19
-3.84
-0.2
Tangible Book Value per Share
-2.24
-0.95
-0.82
-0.75
-0.82
-0.89
-1.4
-1.73
-1.85
-2.51
-3.19
-3.82
-4.47
-0.85
Basic Weighted Avg Shares
21
21
21
21
21
21
21
21
21
21
21
21
21
21
Sales/Revenue/Turnover
114
122
123
124
127
124
124
114
111
107
102
114
118
124
Operating Margin (%)
-3.47
26.43
6.56
4.67
4.9
2.3
-2.22
1.36
1
-9.51
-9.05
-3.5
-5.18
6.68
Depreciation Expense
6
6
5
5
5
6
12
12
11
11
10
13
9
5
Net Income, GAAP
-13
27
2
1
-1
-2
-10
-10
-3
-14
-14
-13
-14
2
Effective Tax Rate (%)
- -
2.46
17.84
- -
268.13
- -
- -
- -
- -
- -
- -
- -
- -
18.5
Profit Margin (%)
-11.2
22
1.91
0.89
-1.15
-1.27
-8.24
-8.42
-2.3
-13.19
-13.94
-11.54
-11.74
1.79
Working Capital
-65
-55
-15
-16
-15
-18
-75
-22
-25
-39
-54
-116
-74
-15
LT Debt
31
41
77
74
73
98
90
152
138
111
106
48
110
75
Total Equity
-32
-6
-3
-2
-4
-5
-16
-23
-25
-39
-54
-67
-81
-4
Return on Invested Capital (%)
- -
43.95
7.81
- -
-12.21
- -
- -
- -
- -
- -
- -
- -
- -
8.15
Return on Capital (%)
- -
43.62
7.78
- -
-12.53
- -
- -
- -
- -
- -
- -
- -
- -
8.15
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

EUR

•

in mil. unless spec.
Sep'15
Dec'15
Jun'16
ST Debt
13
12
13
LT Borrowings
- -
71
- -
LT Finance Leases
- -
6
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
33
27
30

Working Capital

EUR

•

in mil. unless spec.
Sep'15
Dec'15
Jun'16
Total Current Assets
15
15
15
Cash, Cash Equivalents & STI
5
6
7
Accounts Receivable, Net
9
7
8
Inventories
- -
- -
- -
Total Current Liabilities
32
30
30
Payables & Accruals
- -
- -
- -
ST Debt
13
12
13
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
45.74%
29.56%
20.57%
Free Cash Flow
-138.82%
-258.89%
-19.45%
Net Income, GAAP
64.32%
75.02%
5.28%
Sales/Revenue/Turnover
-0.31%
0.82%
3.53%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
25
- -
102
2024
- -
- -
114
2025
- -
- -
118

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
-0.16
- -
-0.68
2024
- -
- -
-0.63
2025
- -
- -
-0.66

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

CEO
Mario Augusto Ruano-Wohlers
Full Time Employees
1,955
Sector
Health services
Industry
Medical/Nursing services
Address
FranzOesische Strasse 53 - 55 Berlin BE Germany 10117
IPO Date
Apr 2, 1997
Business
Maternus-Kliniken AG operates senior living and care facilities, rehabilitation clinics, and service companies in the German healthcare market, focusing on geriatric care and rehabilitation medicine. The company, founded in 1877 and headquartered at Französische Strasse 53-55 in Berlin, Germany, provides retirement and nursing homes; rehabilitation and follow-up treatment services; emergency call systems; assisted living; domestic, inpatient, short-term, and disability care; and home care support through its network of establishments. It serves elderly patients and those requiring post-acute care primarily in Germany. In 2024, Maternus-Kliniken AG implements a strategic measures package, including investments in professionalization that improve occupancy rates, reduce costs, modernize IT infrastructure, and achieve personnel successes; the company also reports improved group revenue and EBITDA in the first half of 2024 and 2025, exceeding expectations and prompting upward revisions to its full-year forecasts.